Hemab Therapeutics Holdings, Inc. (COAG): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Hemab Therapeutics Holdings, Inc. (COAG) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 24, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Direct

Event · Exec change
Person
Keli Walbert
Title
member of the Board
Action
elected
Effective
September 24, 2026

Facts are quoted from the filing text and checked against it.

Original reporting
Published Sep 24, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$COAG
Neutral
medium confidence
Mentioned
$COAG
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$COAGNeutralLow
01

Why it matters

The appointment is a routine corporate governance event with limited immediate price impact.

02

Market read

Primary corporate action for a micro‑cap; low trading relevance.

03

What to watch

Potential hidden strategic initiatives tied to the new director's background are not disclosed.

Relevance 6/10Novelty 5/10Timing: filed Sep 24 2026

Background

SEC Form 8‑K filing details board election and compensation for Hemab Therapeutics.

Company-level read

Ticker impact

$COAGNeutralMedium confidence
Context

Hemab Therapeutics filed an 8‑K announcing the election of Keli Walbert to its board and her compensation package.

Expected impact

Limited short‑term movement, potential slight upside if investors view board change positively.

Evidence & confidence

Director appointments are routine for micro‑caps; no material deal or financial change disclosed.

Market effects

Minimal effect on biotech sector; similar micro‑cap board changes are common.

None

None

Counterpoint

Investors could view the new director as a catalyst for strategic shifts, but evidence is lacking.

Key entities

  • Hemab Therapeutics Holdings, Inc.

    Biotech firm filing the 8‑K.

  • Keli Walbert

    Newly elected Class I director and audit committee member.

Related articles

$COAGMed

Hemab Therapeutics Holdings Inc (COAG) (Q3 2026) Earnings Call Highlights: Pivotal SOLARA

Hemab Therapeutics (COAG) discussed its SOLARA Phase III trial and HMB002 data in its Q3 2026 earnings call. CEO Benny Sorensen highlighted a 50%+ reduction in annualized treated bleed rate for von Willebrand disease, with data covering Type 1 and 2A patients. The trial requires a minimum annualized treated bleed rate of four at entry. HMB002 aims to correct underlying pathophysiology and is monitorable by clinicians.

$COAGMedAI 8/10

Hemab (COAG) Q3 2026 Earnings Call Transcript

Hemab (COAG) reported Q3 2026 progress, including Phase I trial initiation for HMB-003, Phase III trial start for sutacimig in Glanzmann thrombasthenia, and preclinical data for HMB-002. The company added Keli Walbert to its board and is building its commercial strategy. Sutacimig showed promising results in reducing bleeds, and HMB-003 aims to address heavy menstrual bleeding, a condition affecting millions of women.

$COAGMedAI 8/10

What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call

Hemab Therapeutics (COAG) reported a Q3 net loss of $27.3 million, up from $17.1 million a year earlier. The company plans to present updated Phase 2b data for its Factor VII deficiency treatment and new data for its von Willebrand disease treatment in 2027. Preclinical data for its heavy menstrual bleeding candidate will also be presented in December. R&D expenses rose to $24.6 million, driven by clinical program advances.

High

Why is Hemab Therapeutics stock sliding today?

Hemab Therapeutics (HMAB) shares fell 5.3% premarket after reporting a wider Q3 2026 net loss of $27.3M ($0.58/share), up from $17.1M YoY, due to higher R&D and admin costs. CEO Benny Sørensen noted pipeline progress, including a Phase 3 study start. Cash reserves were $430.2M. LifeSci Capital initiated coverage with an Outperform rating and $65 target. Broader market declines also pressured the stock.

Med

Hemab Therapeutics Posts Q3 2026 Net Loss of $27.3 Million

Hemab Therapeutics reported a Q3 2026 net loss of $27.3M, up from $17.1M a year earlier, due to increased R&D and administrative expenses. The company had $430.2M in cash and expects it to last until 2029. Key developments include a Phase 3 trial launch for sutacimig and a Phase 1 trial for HMB-003.

$COAGMedAI 8/10

Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Hemab Therapeutics Holdings, Inc. (COAG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone A